No Hypertensive Disorder of Pregnancy; No Preeclampsia-eclampsia; No Gestational Hypertension; No Hellp Syndrome. Vascular Disorder of Pregnancy Speaks for All

Hypertensive disorders complicate 5%-10% of pregnancies with increasing incidence mainly due to upward trends in obesity globally. In the last century, several terminologies have been introduced to describe the spectrum of this disease. The current and widely used classification of hypertensive pregnancy disorders was introduced in 1972 and in 1982, but has not been free of controversy and confusion. Unlike other diseases, the existing terminology combines signs and symptoms, but does not describe the underlying pathology of the disease itself. In this commentary, a detailed account is given to vascular disorder of pregnancy (VDP) as an inclusive terminology taking into account the underlying pathology of the disease on affected organs and systems. A simple and uniform classification scheme for VDP is proposed.

[1]  F. Figueras,et al.  Characterization of Atypical Preeclampsia , 2015, Fetal Diagnosis and Therapy.

[2]  S. Davidge,et al.  Molecular mechanisms of maternal vascular dysfunction in preeclampsia. , 2015, Trends in molecular medicine.

[3]  B. Nagy,et al.  Genetic Aspects of Preeclampsia and the HELLP Syndrome , 2014, Journal of pregnancy.

[4]  D. Henderson-smart,et al.  Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. , 2014, The Cochrane database of systematic reviews.

[5]  M. Gabryś,et al.  Inability to have children caused by recurrent HELLP syndrome in early pregnancies - implications for a review of literature. , 2013, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[6]  E. Stekkinger,et al.  Metabolic syndrome and the risk for recurrent pre‐eclampsia: a retrospective cohort study , 2013, BJOG : an international journal of obstetrics and gynaecology.

[7]  K. Heimdal,et al.  Pathogenesis of the syndrome of hemolysis, elevated liver enzymes, and low platelet count (HELLP): a review. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[8]  S. Tyagi,et al.  Late postpartum eclampsia , 2012, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[9]  N. Vitoratos,et al.  Molecular Mechanisms of Preeclampsia , 2012, Journal of pregnancy.

[10]  D. Schust,et al.  Preeclampsia: multiple approaches for a multifactorial disease , 2012, Disease Models & Mechanisms.

[11]  R. Bahado-Singh,et al.  Delayed Postpartum Preeclampsia and Eclampsia: Demographics, Clinical Course, and Complications , 2011, Obstetrics and gynecology.

[12]  Mandy J. Bell A historical overview of preeclampsia-eclampsia. , 2010, Journal of obstetric, gynecologic, and neonatal nursing : JOGNN.

[13]  B. LaMarca,et al.  The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. , 2010, Minerva ginecologica.

[14]  J. Tukur The use of magnesium sulphate for the treatment of severe pre-eclampsia and eclampsia. , 2009, Annals of African medicine.

[15]  Eric Jauniaux,et al.  Antihypertensive Therapy and Central Hemodynamics in Women With Hypertensive Disorders in Pregnancy , 2009, Obstetrics and gynecology.

[16]  P. Gracia,et al.  Maternal deaths due to eclampsia and HELLP syndrome , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[17]  A. Fukamizu,et al.  Pathophysiology of placentation abnormalities in pregnancy-induced hypertension , 2008, Vascular health and risk management.

[18]  A. Tranquilli,et al.  HELLP syndrome and placental inflammatory pathology. , 2008, Minerva ginecologica.

[19]  B. Sibai,et al.  HELLP syndrome: an atypical presentation. , 2008, American Journal of Obstetrics and Gynecology.

[20]  G. Krikun,et al.  The Placental Syncytium and the Pathophysiology of Preeclampsia and Intrauterine Growth Restriction , 2008, Annals of the New York Academy of Sciences.

[21]  A. Seicean,et al.  HELLP syndrome - a multisystemic disorder. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[22]  A. Hingorani,et al.  Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis , 2007, BMJ : British Medical Journal.

[23]  R. Harskamp,et al.  Preeclampsia: At Risk for Remote Cardiovascular Disease , 2007, The American journal of the medical sciences.

[24]  M. Permezel,et al.  Gestational Diabetes Mellitus: Clinical Predictors and Long-Term Risk of Developing Type 2 Diabetes , 2007, Diabetes Care.

[25]  M. Olovsson,et al.  The risk of maternal ischaemic heart disease after gestational hypertensive disease. , 2006, BJOG : an international journal of obstetrics and gynaecology.

[26]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[27]  I. Duncan Pre-eclampsia, eclampsia and the thrombotic microangiopathic syndromes of pregnanacy , 2005 .

[28]  A. Smit,et al.  Abnormal Endothelium-Dependent Microvascular Reactivity in Recently Preeclamptic Women , 2005, Obstetrics and gynecology.

[29]  B. Sibai Diagnosis, prevention, and management of eclampsia. , 2005, Obstetrics and gynecology.

[30]  MarkA. Brown Pre‐eclampsia: a lifelong disorder , 2003, The Medical journal of Australia.

[31]  B. Cha,et al.  Metabolic Syndrome and Cardiovascular Disease , 2003 .

[32]  R. Crupi,et al.  A current concept of eclampsia. , 2003, The American journal of emergency medicine.

[33]  J. Kuller,et al.  Preeclampsia into eclampsia: toward a new paradigm. , 2000, American journal of obstetrics and gynecology.

[34]  B. Sibai,et al.  Eclampsia. VIII. Risk factors for maternal morbidity. , 2000, American journal of obstetrics and gynecology.

[35]  K. Lim,et al.  Circulating Factors as Markers and Mediators of Endothelial Cell Dysfunction in Preeclampsia , 1998, Seminars in reproductive endocrinology.

[36]  M. Jacobs,et al.  HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) pathophysiology and anesthetic considerations. , 1997, AANA journal.

[37]  C. Redman,et al.  Eclampsia in the United Kingdom , 1994, BMJ.

[38]  F. Rengo,et al.  Hemodynamic effects of magnesium sulfate on the normal human heart. , 1991, The American journal of cardiology.

[39]  B. Sibai The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? , 1990, American journal of obstetrics and gynecology.

[40]  T. N. Abdella,et al.  Eclampsia: V. The incidence of nonpreventable eclampsia , 1986 .

[41]  O. Ratnoff,et al.  Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. , 1954, The New England journal of medicine.

[42]  D. Hawks The American College of Obstetricians and Gynecologists (ACOG) , 2014 .

[43]  B. Sibai HIGH-RISK PREGNANCY SERIES: AN EXPERT’S VIEW Diagnosis, Controversies, and Management of the Syndrome of Hemolysis, Elevated Liver Enzymes, and Low Platelet Count , 2004 .

[44]  B. Sibai,et al.  Biochemical corroboration of endothelial involvement in severe preeclampsia. , 1995, American journal of obstetrics and gynecology.